HIV and accessory proteins

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
-
<StructureSection load='2MA9' size='350' side='right' scene='' caption=''>
+
<StructureSection load='2MA9' size='350' side='right' scene='' caption='HIV virion infectivity factor (grey) complex with elongin-B (green) and elongin-C (pink) (PDB code [[2ma9]])'>
== Introduction ==
== Introduction ==
Human immunodeficiency virus attacks the immune system by destroying CD4+ T cells, white blood cells that protect the body from infection. During HIV’s initial attack, it attaches to CD4 receptor cells injecting its RNA genetic material. The enzyme reverse transcriptase converts its’ RNA into DNA allowing HIV to use the CD4 cell’s machinery to replicate itself and travel through the body. As the virus attacks these cells, the immune system becomes weaker so the body is unable to fight infection, leading to the development of AIDS. Although HIV can be treated through the use of antiretroviral therapy there is currently no cure <ref name="Cycle">The HIV Life Cycle. (2015) Retrieved from [https://aidsinfo.nih.gov/education-materials/fact-sheets/19/73/the-hiv-life-cycle AIDSinfo]</ref>. HIV’s vast genetic variability makes treatment difficult. This variability is due to the high mutation and recombination rates of the reverse transcriptase enzyme causing HIV viral sequences to differ by up to 10% in each individual <ref name="Hemelaar">Hemelaar, J. (2012). The Origin and Diversity of the HIV-1 pandemic.In Trends in Molecular Medicine, 18(3):182-192 [http://doi.org/10.1016/j.molmed.2011.12.001 DOI:10.1016]</ref>. An estimated 36.9 million people were suffering from HIV around the world in 2014 <ref name="Global">Global HIV and AIDS Statistics. (2015). Retrieved from [http://www.avert.org/professionals/hiv-around-world/global-statistics Averting HIV and AIDS.]</ref>.
Human immunodeficiency virus attacks the immune system by destroying CD4+ T cells, white blood cells that protect the body from infection. During HIV’s initial attack, it attaches to CD4 receptor cells injecting its RNA genetic material. The enzyme reverse transcriptase converts its’ RNA into DNA allowing HIV to use the CD4 cell’s machinery to replicate itself and travel through the body. As the virus attacks these cells, the immune system becomes weaker so the body is unable to fight infection, leading to the development of AIDS. Although HIV can be treated through the use of antiretroviral therapy there is currently no cure <ref name="Cycle">The HIV Life Cycle. (2015) Retrieved from [https://aidsinfo.nih.gov/education-materials/fact-sheets/19/73/the-hiv-life-cycle AIDSinfo]</ref>. HIV’s vast genetic variability makes treatment difficult. This variability is due to the high mutation and recombination rates of the reverse transcriptase enzyme causing HIV viral sequences to differ by up to 10% in each individual <ref name="Hemelaar">Hemelaar, J. (2012). The Origin and Diversity of the HIV-1 pandemic.In Trends in Molecular Medicine, 18(3):182-192 [http://doi.org/10.1016/j.molmed.2011.12.001 DOI:10.1016]</ref>. An estimated 36.9 million people were suffering from HIV around the world in 2014 <ref name="Global">Global HIV and AIDS Statistics. (2015). Retrieved from [http://www.avert.org/professionals/hiv-around-world/global-statistics Averting HIV and AIDS.]</ref>.

Revision as of 11:02, 7 January 2018

HIV virion infectivity factor (grey) complex with elongin-B (green) and elongin-C (pink) (PDB code 2ma9)

Drag the structure with the mouse to rotate

References

  1. The HIV Life Cycle. (2015) Retrieved from AIDSinfo
  2. Hemelaar, J. (2012). The Origin and Diversity of the HIV-1 pandemic.In Trends in Molecular Medicine, 18(3):182-192 DOI:10.1016
  3. Global HIV and AIDS Statistics. (2015). Retrieved from Averting HIV and AIDS.
  4. 4.0 4.1 Origin of HIV & AIDS. (2015). Retrieved from Averting HIV and AIDS.
  5. Where Did HIV Come From? (2011). Retrieved from The AIDS Institute
  6. 6.0 6.1 Rose, Kristine M., Marin, Mariana, Kozak, Susan L., Kabat, David. (2004). The viral infectivity factor (Vif) of HIV-1 unveiled. TRENDS in Molecular Medicine, 10(6), 291-297.
  7. Morellet, N., Bouaziz, S., Petitjean, P., Roques, B. P. (2003). NMR Structure of the HIV-1 Regulatory Protein VPR. J. Mol. Biol, 327, 215-227.
  8. 8.0 8.1 Oie Solbak, Sara Marie, Reksten, Tove Ragna, Hahn, Friedrich, Wray, Victor, Henklein, Petra, Henklein, Peter, Halskau, Oyvind, Schubert, Ulrich, Fossen, Torgils. (2013). HIV-1 p6 - a structured to flexible multifunctional membrane-interacting protein. Biochimica et Biophysica Acta, 1828, 816-823.
  9. 9.0 9.1 Das, S.R., Jameel, S. (2005). Biology of the HIV Nef protein. Indian Journal of Medical Research, 121(4), 315-332.
  10. 10.0 10.1 Blissenbach, M., Grewe, B., Hoffman, B., Brandt, S., Uberla, K. (2010). Nuclear RNA export and packaging functions of HIV-1 Rev revisited. Journal of Virology, 84(13), 6598-604.
  11. 11.0 11.1 Das, A. T., Harwig, A., & Berkhout, B. (2011). The HIV-1 Tat Protein Has a Versatile Role in Activating Viral Transcription. Journal of Virology, 85(18), 9506–9516.
  12. Yao, S., Torres, A.M., Azad, A.A., Macreadie, I.G., Norton, R.S. (1998) Solution structure of peptides from HIV-1 VPR protein that cause membrane permeabilization and growth arrest. J.Pebt.Sci. 4.426-435
  13. Demirov, Dimiter G., Orenstein, Jan M., and Freed, Eric O., (2002). The late domain of Human Immunodeficiency Virus type 1 promotes virus release in a cell type-dependent manner. Journal of Virology. 71(1), 105-117.
  14. 14.0 14.1 14.2 14.3 Shors, Teri. (2011). Understanding Viruses. (2nd ed., pp. 507-511). Oshkosh, Wisconsin: Jones and Bartlett.
  15. Fernandes, J., Jayaraman, B., & Frankel, A. (2012). The HIV-1 Rev response element: An RNA scaffold that directs the cooperative assembly of a homo-oligomeric ribonucleoprotein complex.RNA Biology, 9(1), 6–11.

Proteopedia Page Contributors and Editors (what is this?)

Michal Harel, Erin Bolger, Alexander Berchansky, Joel L. Sussman

Personal tools